



Early intervention with ABA prevents neuroinflammation and memory impairment  in a triple 
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• Abscisic Acid (ABA) treatment can effectively prevent memory impairment in a murine model of 
Alzheimer disease (AD). 
• ABA treatment can prevent microglia transition to inflammatory state in transgenic model of AD. 
• The beneficial effects of ABA, PPARᵧ agonist and an insulin sensitizer in the central nervous 
system are independent of peripheral insulin resistance. 
• Further studies will establish whether later intervention (when the disease may be in initial 




ABA, Abscisic acid;  
AD, Alzheimer disease 
APP, Amyloid precursor protein;  
PFA, paraformaldehyde  
PPAR-γ, Peroxisome proliferator-activated receptor gamma;  
SEM, Standard error of mean.  
TNFα, Tumour necrosis Factor α 




Neuroinflammation and insulin resistance in the brain are intimately linked to neurodegenerative disorders, 
including Alzheimer’s disease. Even though traditionally Alzheimer´s disease has been associated to  
deposits and hyperphosphorylated Tau intracellular tangles, several studies show that neuroinflammation 
may be the initial cause that triggers degeneration. Accordingly, a number of natural supplements that 
improves brain insulin sensitivity and reduce neuroinflammation have been proposed as good choices in 
the therapeutic prevention of cognitive decline. Further supporting this evidence, we show that 
phytohormone Abscisic Acid, can prevent memory impairment and neuroinflammation markers in a triple 
transgenic mouse model, where no peripheral inflammatory changes have occurred. Moreover, our data 
strongly suggests that early intervention is critical for good prognosis, and that cognitive improvement 
requires longer treatment than recovering neuroinflammation markers. 
 
Main text  
A large body of evidence has accumulated correlating chronic inflammatory processes that results in 
neuronal toxicity and the development of neurodegenerative pathologies [1], including Alzheimer’s disease 
[2, 3]. In line with this, several extrinsic factors such as physical exercise, supplementary dietary 
compounds and relaxing methods exert their beneficial effects on brain most likely due to their capability 
of reducing chronic and sustained inflammation. Consequently, synaptic plasticity [4] and memory [5, 6] 
are greatly ameliorated. Neuroinflammation is characterized by an important increase of reactive microglia, 
which secretes proinflammatory cytokines (e.g. TNFα, IL1β). Sustained high levels of these cytokines 
result in brain insulin resistance and further neuronal toxicity. Preventing microglia inflammatory state has 
been associated to improved spatial memory [7]. Thus, phytohormones can be considered neuroprotectors 
due to their anti-inflammatory properties [8]. Previous work in our group lab have shown that, ABA, a 
3 
 
PPARP agonist [9] can improve glucose tolerance in obesity models, reduce neuroinflammation and 
restore cognitive function in a HFD-induced neuroinflammation model [10–13].  
We hypothesized that ABA could have a potential beneficial effect in a genetic model of 
neuroinflammation, unrelated to obesity or peripheral insulin resistance. In this study, we have made use 
of a well-established model of synaptic dysfunction, the triple transgenic mice (3xTg-AD) to evaluate the 
effects of the phytohormone ABA in hippocampal-dependent cognitive tasks, in correlation with 
neuroinflammation processes. This murine model of Alzheimer is homozygous for all three mutant alleles 
(Psen1 mutation; APPSwe and tauP301L) transgenes. These are based on human mutations identified in 
Familial AD [14]. The procedures followed directive 86/609/EEC of the European Community on the 
protection of animals used for experimental and other scientific purposes. The experiments were approved 
by the Ethics Committee of the University Jaume I (approval number 2014/VSC/PEA00209).  
Control and transgenic mice (total of 78) were divided randomly into four experimental groups: ABA3 and 
ABA5, animals supplemented with ABA (Fernandez-Rapado, Spain) in their drinking water (20 mg/L) for 
3 or 5 months respectively. Control groups where administered vehicle for 3 or 5 months (VEH3 or VEH5 
respectively). The number of animals per group was 8-10. All groups were fed ad libitum for 8 months. At 
that age, all experimental groups were subjected to behavioural tests prior to sacrifice (Fig 1). 
The Novel Object Recognition (NOR) paradigm exploits the innate preference exhibited by rodents to 
explore novel objects. This paradigm evaluates the capability of the animal to remember a familiar object 
compared to a new one. We observed no significant differences in the time spent exploring the identical 
objects during familiarization phase (Fig. 2A). When an object was substituted for a new one (test phase), 
control mice spent 71± 0.03% or 72±0.05% of the total test time sniffing the new object (VEH 3 and VEH 
5 respectively). On the other hand, transgenic mice spent 53±0.05% and 58±0.05% of the total test time 
sniffing the novel object, which indicates that transgenic mice do not remember the familiar as well and 
thus explore both objects almost equally. When mice were treated with ABA, controls behaviour did not 
change respect to their vehicle-administered littermates (73±0.07 % and 70 ±0.03% respectively). Triple 
transgenic mice had a slight improvement in memory after 3months of ABA treatment (66±0.1%) but this 
increase was not significant. However, 5 months ABA treatment completely restored memory in transgenic 
mice, that behaved as controls (76±0.06% time exploring the novel object) (Fig. 2B) **p<0.01 respect to 
control and ## p<0.01 respect to 3xTg VEH5. Data are expressed as the percentage of the total time of the 
test that the animal spends sniffing the novel object. Data passed normality test and was analysed with 
unpaired Student t-test for differences. Moreover, transgenic mice at this age did not differ from controls 
in social preference, nor did ABA treatment affect this behaviour (Fig 2C). Moreover, social memory was 




In this study we confirmed that short-term memory was deficient in transgenic mice compared to controls, 
whereas social discrimination and social memory were no different from controls. This could be consistent 
with an early sign of hippocampal dependent task in Alzheimer patients and different of other dementias 
[15]. We found that the longest treatment with ABA (5 months) but not short term (3 months) completely 
rescued object recognition impairment. This finding could be explained either because the effect is due to 
early the intervention (the long treatment started when the mice were only 3 month of age), before 
irreversible neurological damage has occurred. The other, more hopeful alternative is that longer treatment 
is required to effectively reverse the toxic consequences of Alzheimer-inducing mutations. Further 
experimental designs will be required to elucidate between these possibilities.  
Microglia morphology has been demonstrated to correlate with their activation state [16]. Thus, in healthy 
conditions, the microglia display a branched morphology. Although these microglia cells are called 
“resting· microglia, they are actually in a surveillant activity, where branches are used to scrutinize the 
environment and regulate neuronal activity [17]. In inflammatory conditions, or after any kind of injury, 
microglia undergo a stepwise de-ramification process, acquiring a more rounded morphology, with fewer 
branches. In this morphological state, microglia are known as pro-inflammatory or “reactive”. Both 
microglia phenotypes display a distinct pattern of cytokines secretion. Several studies have validated a 
quantification method to evaluate the microglia morphology and transitions from resting to reactive 
inflammatory state [18, 19].  
The murine models of Alzheimer disease exhibit microglia in an inflammatory state, mostly due to the 
accumulation of toxic misfolded proteins. Therefore, we set out to examine the microglia morphology in 
two brain areas that are involved in memory, the prefrontal cortex and the hippocampus). To evaluate 
microglia, immunodetection of Iba-1, microglia marker was carried out as described [10–13]. Briefly, mice 
were anesthetized with pentobarbital (120 mg/kg Eutanax, Fatro, Barcelona, Spain) and transcardially 
perfused with saline and 4 % paraformaldehyde (PFA) fixative. Sliding Microtome Leica SM2010R (Leica 
Microsystems, Heidelberg, Germany) was used to obtain 40-μm thick coronal frozen sections. Sections 
were rinsed and incubated in blocking solution for 1 h followed by primary antibody incubation anti-IBA-
1 (ab5076; Abcam 1:500). After several washes, the slides were incubated with the biotinylated secondary 
antibody (Jackson 1: 200). Signal was detected using the VECTASTAIN® Elite® ABC-HRP Kit; 
Peroxidase, Standard, USA) and colour reaction with DAB (Sigma-Aldrich, St Louis, MO, USA) for 15-
20 minutes. The slices were and cover-slipped with a DPX mounting medium.   
A total of 5 cells per brain area (prefrontal cortex and/or hippocampus) were randomly selected in each 
animal per experimental groups (n=4). The following microglia morphological parameters were analysed 
with FIJI free software: fractal dimension (D); this parameter evaluates cellular branching complexity. 
High D values correspond to a greater cellular complexity; cell area is the total number of pixels 
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corresponding to the area occupied by the cell, soma and branches, thus the higher the area the microglia is 
considered in resting state. Finally, cell perimeter is measured based on the single outline cell shape, thus, 
the higher the ramification, the higher this value and the microglia is considered polarized into a less 
inflammatory state [18, 19]. Data are expressed as mean ± SEM of the 4 animals and subjected to a 
Kolmogorov-Smirnov normality test. Since the sample was small, Mann Whitney non-parametric test was 
applied. 
We observed that transgenic mice treated with vehicle had clear inflammatory microglia compared to 
control mice, both in hippocampus (Fig 3) and in prefrontal cortex (Fig 4) areas.  Interestingly, both short- 
and long-term ABA treatment prevented the inflammatory conversion of microglia, in both areas, as 
demonstrated by the quantification of specific parameters. Fractal, area and perimeter are statistically 
different between control and 3xTg (treated with VEH 3 and VEH 5); whereas transgenic mice treated with 
ABA 3 and ABA5 showed no difference with their respective controls. Furthermore, 3xTg ABA3 and 
ABA5 were significantly different from 3xTg vehicle treated experimental groups. 
*
p<0.05 indicates that 
3xTg VEH is significantly different of control VEH; whereas # p<0.05 indicates that 3xTg ABA is 
significantly different of 3xTg VEH. 
ABA targets peroxisome proliferator-activated receptor gamma (PPAR-γ) in a similar manner as the 
thiazolidinedione class of anti-diabetic drugs [20] and curcumin [21]. This family of PPAR-γ agonist 
molecules has been proposed as a new class of therapeutic molecules to treat central nervous system 
disorders [22]. Consistently, we have demonstrated the beneficial effects of ABA in a neuroinflammation 
model induced by high fat diet [10, 13].  
Whether or not ABA activates microglia has been controversial. In vitro studies have shown that ABA may 
induce activation of microglial cell line N9 via calcium influx [23], where others have not confirmed this 
activation [24]. In our model, we have clearly demonstrated that ABA chronic exposure (3 and 5 months) 
can effectively reduce (or prevent) microglia chronic activation as measured by morphological parameters 
of perimeter, area and fractal dimension. However, this reduction in proinflammatory state does not totally 
correlate with improvement in spatial memory, since 3 months ABA exposure effectively prevented 
microglia conversion to inflammatory state, but did not rescue behaviour. This suggests that microglia state 
is not enough in itself to guarantee optimal neuronal performance, but it is very likely an early event, prior 
to the improvement of neuronal health, and subsequent optimal cognitive task performance. In addition, 
ABA does not affect controls, suggesting that is a safe procedure.  
Considering all these data, we conclude that ABA can effectively prevent memory deficits in a model of 
neuroinflammation induced by Alzheimer-like mutations, supporting the beneficial effects on memory that 
we have reported previously in a model of neuroinflammation due to high fat diet. These data broad up the 
applications of safe and natural anti-inflammatory supplements in a variety of pathologies mediated but 
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chronic inflammation, especially in the elderly.  In addition, we show that early intervention may be crucial 
and therefore prompt for the early detection to prevent neurological irreversible damage with better chances 
of delaying or avoiding disease, even in the hereditary forms of the disease. 
In conclusion in this study, we have evaluated the effects of ABA chronic short (3 months) and long for (5 
months) treatment. All mice were sacrificed at 8 months, which means that long treatment started in young 
adult animals, before the neurological damage is suspected in this model. We have shown that the long but 
not the short treatment can prevent memory deficits. However, to our surprise, ABA both long and short 
term administration prevented hippocampal and prefrontal cortex microglia inflammatory state, suggesting 
that microglia resting state is not sufficient for optimal cognitive function, but it probably precedes it.  Our 
results indicate that ABA can be an effective supplement to improve cognitive health in neuropathologic 
situations. Moreover, early intervention and/or longer treatments may be critical to prevent cognitive 
decline.   
 
 
Figure 1.  Experimental design. 3xTg and C57BL/6 male mice were treated with ABA (20mg/L) or 
vehicle in the drinking water. Treatment was administered for 5months (VEH 5M or ABA 5M), 
starting at 3months of age; and 3months (VEH 3M or ABA 3M), starting at 5 months of age. A 
week prior to sacrifice all groups performed behavioural tests as depicted. All groups were sacrificed 
at 8 months of age.  
Figure 2. ABA chronic administration improves memory in triple transgenic mice. Novel object 
recognition paradigm, time exploring two objects during familiarization phase is similar in all 
groups (A). Time exploring the novel object during test phase is lower in 3xTg but recover with 
5months ABA treatment (B). In a three-chamber social interaction and memory test, Sociability (C) 
nor Social memory was altered by genotype or ABA treatment (D). Data expressed as the mean and 
SEM of n=6-10 individuals *p<0.05; **p<0.01 respect to control;  ## p<0.01 respect to 3xTg VEH5 
(one tail Student t-test).  
Figure 3. Microglia in hippocampus CA1.  (A) Microglia from transgenic mice with 3 and 5 month 
vehicle treatment shows a proinflammatory morphology compared to wild type control. ABA 
treatment for 5 and 3 months rescues microglia morpholgy in transgenic mice and does not alter 
control. (B) Quantification of morphological characteristics showed that fractal, area and perimeter 
characteristics are lower in vehicle treated transgenic mice compared to control. ABA administration 
for 3 and 5 months rescued microglia morpholgy to control parameters while does not significantly 
affect wild type mice. Data expressed as the mean and SEM of 4 animals per group (5 cells per 
Bregma level). Control (black squares) and 3xTg (white circles).  *p<0.05 significant difference 
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3xTg3 VEH versus control VEH ;  # p<0.05 3xTg ABA versus 3xTg VEH (Mann Whitney test).  
Figure 4. Microglia in Prefrontal cortex.  (A) Microglia from transgenic mice with 3 and 5 month vehicle 
treatment shows a proinflammatory morphology compared to wild type control. ABA treatment for 
5 and 3 months rescues microglia morpholgy in transgenic mice and does not alter control. (B) 
Quantification of morphological characteristics showed that fractal, area and perimeter 
characteristics are lower in vehicle treated transgenic mice compared to control. ABA administration 
for 3 and 5 months rescued microglia morphology to control parameters while does not significantly 
affect wild type mice. Data expressed as the mean and SEM of 4 animals per group (5 cells per 
Bregma level). Control (black squares) and 3xTg (white circles).  *p<0.05 significant difference 
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